Orthofix(US:OFIX)2026-02-24 14:32Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP Adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. Limb Reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][5] Market Data and Key Metrics Changes - U.S. Limb Reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered strong sequential fourth quarter growth, reaching 7%, more than double the market rate [8] - The company expects to return to double-digit growth in the second half of 2026 for U.S. Limb Reconstruction as portfolio refinements take hold [14] Company Strategy and Development Direction - The company has rebranded its orthopedics business as Limb Reconstruction, focusing on high-value clinical categories with an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization, extending the timeline to 2028 [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by a focused distributor network and innovation pipeline [11][25] - The company is committed to disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [24][27] - Management highlighted the importance of ongoing product launches and enhancements across all business segments to drive sustained momentum [26] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted gross margins for the full year 2026 are expected to be approximately 72.5% [18] - The company anticipates $45 million-$50 million in capital expenditures for the year [22] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [32] Question: Long-range plan and margin improvement - Management explained that the extended timeline reflects the need for a stronger foundation and focus on market execution, with ongoing efforts to improve gross margins and cash generation [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with a return to double-digit growth in the second half of 2026 for limb reconstruction [42] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and emphasized a renewed focus on advancing the biologics portfolio [51][52] Question: Tariff impact and legal settlements - Management indicated an expected $1 million-$2 million impact from tariffs in 2026 and confirmed that an accrual for a legal settlement was taken in Q3 [57][62]